Trevi Therapeutics (TRVI) Tops Q4 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg